Zacks Research Has Positive Outlook for HALO Q3 Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Investment analysts at Zacks Research lifted their Q3 2026 earnings per share estimates for shares of Halozyme Therapeutics in a report issued on Tuesday, June 2nd. Zacks Research analyst Team now forecasts that the biopharmaceutical company will post earnings of $1.96 per share for the quarter, up from their prior estimate of $1.86. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $7.60 per share.

Other equities research analysts also recently issued research reports about the company. Wells Fargo & Company raised their target price on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a report on Thursday, February 19th. HC Wainwright upped their price target on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Benchmark increased their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Finally, TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Seven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $80.67.

Halozyme Therapeutics Stock Down 2.7%

Halozyme Therapeutics stock opened at $66.28 on Wednesday. The stock’s 50 day moving average price is $66.24 and its 200 day moving average price is $68.75. Halozyme Therapeutics has a 1-year low of $51.06 and a 1-year high of $82.22. The company has a market cap of $7.86 billion, a PE ratio of 23.84, a price-to-earnings-growth ratio of 0.28 and a beta of 0.88. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. The business had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company’s revenue for the quarter was up 42.2% on a year-over-year basis. During the same period in the prior year, the business posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS.

Insiders Place Their Bets

In other Halozyme Therapeutics news, COO Cortney Caudill sold 8,857 shares of the company’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $67.64, for a total value of $599,087.48. Following the sale, the chief operating officer owned 7,055 shares of the company’s stock, valued at approximately $477,200.20. This represents a 55.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $69.19, for a total value of $691,900.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $53,122,698.20. This represents a 1.29% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 92,107 shares of company stock worth $6,212,534. 2.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. DLD Asset Management LP lifted its holdings in shares of Halozyme Therapeutics by 20.0% in the third quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock valued at $2,200,200,000 after purchasing an additional 5,000,000 shares in the last quarter. Norges Bank purchased a new position in shares of Halozyme Therapeutics during the 4th quarter worth approximately $128,201,000. William Blair Investment Management LLC acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth approximately $124,031,000. Voloridge Investment Management LLC acquired a new position in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $77,587,000. Finally, Qube Research & Technologies Ltd purchased a new stake in Halozyme Therapeutics in the 2nd quarter valued at approximately $51,295,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.